Bill Would Allow AI to Prescribe Drugs

Artificial intelligence (AI) could be used to prescribe medications to patients — if a new bill makes its way through Congress.

The proposed legislationopens in a new tab or window, sponsored by Rep. David Schweikert (R-Ariz.), would amend the Federal Food, Drug, and Cosmetic Act to clarify that AI and machine learning technologies can qualify as a practitioner eligible to prescribe drugs if authorized by the state involved and approved by the FDA.

The bill was introduced in the U.S. House of Representatives and referred to the House Committee on Energy and Commerce in January.

But Adam Rodman, MD, MPH, a hospitalist and director of AI programs at Beth Israel Deaconess Medical Center and assistant professor at Harvard Medical School in Boston, told MedPage Today that the technology is not nearly where it needs to be for this kind of prescribing.

However, “[t]hings are accelerating so quickly,” he added, “I don’t doubt that we will be having this conversation,” at some point.

He said he believes the proposed legislation “reflects enthusiasm about the technology,” and that it could be aimed at helping to address “huge care gaps,” when people struggle to see their doctor.

Still, “there would have to be huge sets of regulations that govern this,” Stephan Fihn, MD, MPH, an internal medicine physician and professor in the departments of medicine and health systems and population health at the University of Washington, told MedPage Today. As it is, the proposed legislation doesn’t specify which drugs it could be used for and in which settings, or whether physician review would be required.

Currently, there are many applications for AI in medicine, and “they’re increasing very rapidly,” said Fihn, who also serves as executive deputy editor of JAMA Network Open. But the application of AI and machine learning technologies, as described in the bill, “seems premature,” as it appears to enable the “actual prescribing of drugs, some of which are very low risk, and some of which are very high risk,” he cautioned.

Similar to autonomous vehicles being held to a higher standard than human drivers, he surmised that AI and machine learning technologies as prescribers would likely be as well. “My suspicion is that there will be a very high bar for approving these, at least initially,” he noted.

Ultimately, “I think it will come to be,” Fihn said. “And to be honest, properly developed, properly tested, properly managed, and highly regulated, it could be a good thing. But this has to be proven and shown.”

Schweikert, the bill’s sponsor, did not immediately provide additional comment to MedPage Today; however, he spoke about AI in healthcare and how it could impact government costs in an interview last year.

“Technology has to be part of the way we bend the borrowing and debt curve,” Schweikert said in the interview with Nextgov/FCWopens in a new tab or window, adding that broader adoption of AI “can make government better, faster, cheaper” in responding to Americans’ needs.

AI can improve diagnostics, Schweikert said, as well as front and back office medical operations.

“It’s here, we now just have to build the infrastructure around it,” he added, referencing a “new medical landscape.” He also noted that “technology is starting to move much faster than our regulatory rules.”

Previously, in January 2023, Schweikert introduced legislation aimed at achieving the same goal as the bill introduced earlier this month, according to Nextgov/FCW. Ultimately, though, the bill did not advance out of committee.

Meanwhile, AI in healthcare has continued to percolate as new uses emerge.

At an online panel discussion hosted by the Kaiser Family Foundation last February, health policy experts discussed the potentialopens in a new tab or window of AI to simplify prior authorization, though they added that “complete transparency” would be needed.

In many ways, AI in healthcare is still uncharted territory, and at the end of 2024 MedPage Today reported that accountability is likely to be key this year, though regulation isn’t necessarily expectedopens in a new tab or window.

In a policy position paper from the American College of Physicians last June, one of the position statements was that AI technologies should complement, not supplantopens in a new tab or window logic and decision making of physicians and other clinicians.

Regarding Schweikert’s current bill, it remains to be seen how far it may advance through the legislative process.

Five years ago, what is being proposed in the bill may have seemed like science fiction, Rodman noted. “This isn’t sci-fi,” he said. “It’s just we aren’t there yet.”

 

Source Link

Recommended Articles

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More

Trump Announces TrumpRx Expansion, Adding 160 More Drugs

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

Read More

Skyrocketing GLP-1 Demand Creates Major Financial Strain For Employers

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...

Read More

Judge Throws Out Policy Imposing $100,000 Fees for Skilled Worker Visas

A Trump administration initiative to impose $100,000 fees on employers seeking visas for skilled foreign workers amounts to an unlawful tax on those companies and must be voided “in its entirety,” a federal judge ruled on Monday. The decision by Judge Leo T. Sorokin of the Federal District Court for the District of Massachusetts nullified ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square